Bain Capital launched Beeline Medicines, a new company seeded with five Bristol Myers Squibb immunology programs after the licensing deal that took place last year. The startup emerged from stealth with a CEO and a named lead asset, afimetoran, positioned for systemic lupus erythematosus as a daily oral therapy. Beeline said it plans to report Phase 2 data later this year and move toward a pivotal program after establishing proof-of-concept. Its pipeline also includes early-stage candidates in atopic dermatitis and lupus and a once-daily TYK2 inhibitor in plaque psoriasis, plus preclinical programs linked to IL-8 and IL-10. This launch matters for immunology because it shows how large-company “shelved” assets can quickly re-enter clinical paths under specialist governance, supported by early-stage capital meant to carry programs toward data-driven partnering or late-stage financing.